Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|
Covariate | P | HR (95% CI) | P | HR (95% CI) |
Sex (ref: Male) | 0.0002 | 0.801 (0.713–0.899) | 0.0003 | 0.792 (0.698–0.900) |
Age (ref: < 75 years old) | 0.0024 | 1.389 (1.123–1.717) | – | – |
Histotype (ref: Other) | ||||
LMS | 0.0004 | 0.765 (0.659–0.888) | 0.0010 | 0.765 (0.652–0.897) |
DLPS | 0.0269 | 1.291 (1.030–1.619) | 0.2034 | 1.171 (0.918–1.492) |
MPNST | 0.1368 | 1.273 (0.926–1.751) | 0.2183 | 1.234 (0.883–1.726) |
SS | 0.4738 | 1.074 (0.883–1.307) | 0.0764 | 1.206 (0.980–1.485) |
UPS | 0.0061 | 1.347 (1.089–1.668) | 0.1839 | 1.168 (0.929–1.469) |
Grade (ref: < 3) | < 0.0001 | 1.692 (1.491–1.920) | < 0.0001 | 1.687 (1.483–1.919) |
Number of metastatic sites (ref: 1) | 0.0136 | 1.200 (1.038–1.387) | 0.0009 | 1.305 (1.115–1.528) |
Liver metastasis (ref: no) | 0.1056 | 0.891 (0.774–1.025) | – | – |
Locoregional treatment (ref: no) | < 0.0001 | 0.412 (0.365–0.465) | < 0.0001 | 0.400 (0.351–0.455) |
Clinical trial (ref: no) | < 0.0001 | 0.750 (0.653–0.862) | 0.0002 | 0.755 (0.651–0.877) |
Off-label drugs (ref: no) | < 0.0001 | 0.791 (0.703–0.890) | – | – |
Anthracycline (ref: no) | 0.0046 | 0.838 (0.741–0.947) | – | – |
Anthracycline in first line (ref: no) | 0.0127 | 0.861 (0.765–0.968) | – | – |
Polychemotherapy in first line (ref: no) | 0.0003 | 0.804 (0.715–0.902) | 0.0023 | 0.822 (0.724–0.932) |